PMID- 37425405 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2218-6751 (Print) IS - 2226-4477 (Electronic) IS - 2218-6751 (Linking) VI - 12 IP - 6 DP - 2023 Jun 30 TI - Five-year follow-up after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer: a multicenter study. PG - 1293-1302 LID - 10.21037/tlcr-23-180 [doi] AB - BACKGROUND: Stereotactic body radiotherapy (SBRT) has proven to provide high rates of tumor control for patients with early-stage non-small cell lung cancer (NSCLC). We are reporting a multicenter experience of long-term clinical outcomes and adverse effect profiles of patients with medically inoperable early-stage NSCLC treated with SBRT. METHODS: A total of 145 early-stage NSCLC patients underwent SBRT at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Shandong Cancer Hospital and Institute, and Shanghai Pulmonary Hospital between October 2012 and March 2019. Four-dimensional computed tomography (4D-CT) simulation was used for all patients. All received a biologically effective dose (BED; alpha/beta=10) of 96-120 Gy with the prescribed isodose line covering >95% of the planning target volume (PTV). Survival was analyzed by the Kaplan-Meier method. Survival was estimated using the Kaplan-Meier method. RESULTS: The median tumor diameter was 2.2 (range, 0.5-5.2) cm. The median follow-up was of 65.6 months. Thirty-five patients (24.1%) developed disease recurrence. The rates of local, regional, and distant disease recurrence were, respectively, 5.1%, 7.4%, and 13.2% at 3 years; and 9.6%, 9.8%, and 15.8% at 5 years. Progression-free survival (PFS) rates at 3 and 5 years were 69.2% and 60.5% respectively; the overall survival (OS) rates were 78.1% and 70.1%, respectively. Five patients (3.4%) experienced grade 3 treatment-related adverse events (AEs). No patient experienced grade 4 or 5 toxicity. CONCLUSIONS: From our retrospective analysis with long-term follow-up in Chinese population, SBRT achieved high rate of local control (LC) and low toxicity in patients with early-stage NSCLC. This study offered robust long-term outcome data of SBRT in the Chinese population, which was very rarely reported in China before. CI - 2023 Translational Lung Cancer Research. All rights reserved. FAU - Guo, Yanling AU - Guo Y AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. AD - School of Medicine, Tongji University, Shanghai, China. FAU - Zhu, Yaoyao AU - Zhu Y AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Zhang, Ran AU - Zhang R AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. AD - School of Medicine, Tongji University, Shanghai, China. FAU - Yang, Shuangyan AU - Yang S AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Kepka, Lucyna AU - Kepka L AD - Department of Radiotherapy, Military Institute of Medicine-National Research Institute, Warsaw, Poland. FAU - Viani, Gustavo Arruda AU - Viani GA AD - Department of Medical Imaging, Hematology and Oncology, Ribeirao Preto Medical School, University of Sao Paulo (FMRP-USP), Sao Paulo, Brazil. FAU - Milano, Michael T AU - Milano MT AD - Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Sio, Terence T AU - Sio TT AD - Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA. FAU - Sun, Xiaojiang AU - Sun X AD - Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. FAU - Wu, Hongyu AU - Wu H AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. FAU - Xing, Ligang AU - Xing L AD - Department of Radiation Oncology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. FAU - Xu, Yaping AU - Xu Y AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20230629 PL - China TA - Transl Lung Cancer Res JT - Translational lung cancer research JID - 101646875 PMC - PMC10326768 OTO - NOTNLM OT - Early-stage non-small cell lung cancer (early-stage NSCLC) OT - patterns of failure OT - stereotactic body radiotherapy (SBRT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-180/coif). MTM reports that he received a speaker fee from Astra Zeneca and royalties from Wolters Kluwer. TTS reports that he provides strategic and scientific recommendations as a member of the advisory board and speaker for Novocure, Inc. and also as a member of the advisory board to Galera Therapeutics and Catalyst Pharmaceuticals, Inc. The other authors have no conflicts of interest to declare. EDAT- 2023/07/10 06:42 MHDA- 2023/07/10 06:43 PMCR- 2023/06/30 CRDT- 2023/07/10 04:56 PHST- 2023/05/04 00:00 [received] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/07/10 06:43 [medline] PHST- 2023/07/10 06:42 [pubmed] PHST- 2023/07/10 04:56 [entrez] PHST- 2023/06/30 00:00 [pmc-release] AID - tlcr-12-06-1293 [pii] AID - 10.21037/tlcr-23-180 [doi] PST - ppublish SO - Transl Lung Cancer Res. 2023 Jun 30;12(6):1293-1302. doi: 10.21037/tlcr-23-180. Epub 2023 Jun 29.